Oramed Pharmaceuticals is a pharmaceutical company. Co. is engaged in the research and development of pharmaceutical solutions, including an oral insulin capsule to be used for the treatment of individuals with diabetes, and the use of orally ingestible capsules or pills for delivery of other polypeptides. Co.'s primary product, ORMD-0801, is an orally ingestible insulin capsule for the treatment of diabetes. In addition to its key product, the ORMD-0801 insulin capsule, Co. is using its technology for an orally ingestible Glucagon-like peptide-1 capsule, or ORMD-0901. Co. is developing a drug candidate, a weight loss treatment in the form of an oral leptin capsule. The ORMP stock yearly return is shown above.
The yearly return on the ORMP stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2023 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the ORMP annual return calculation with any dividends reinvested as applicable (on ex-dates).
|